Respiratory And Thoracic Cancers

Lorbrena Approved for Previously-Treated ALK-Positive Metastatic NSCLC

By November 05, 2018

Lorbrena, a third generation ALK tyrosine kinase inhibitor (TKI), has been approved under the accelerated pathway based on tumor response rate and duration of response.

Keytruda Combo Approved for First-Line Tx of Metastatic Squamous NSCLC

By October 31, 2018

The approval was supported by data from the Phase 3 randomized, double-blind, multicenter, placebo-controlled KEYNOTE-407 trial.

Commonly Prescribed Antihypertensives Linked to Increased Lung Cancer Risk

By October 29, 2018

To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.

Durvalumab Extends Survival vs Placebo in Stage 3 Non-Small Cell Lung CA

October 29, 2018

Overall survival was significantly prolonged with durvalumab versus placebo (stratified hazard ratio [HR] for death, 0.68; P=.0025). For progression-free survival, the median duration was 17.2 months in the durvalumab group and 5.6 months in the placebo group.

Survival Time Compared for Brigatinib vs Crizotinib in NSCLC

October 16, 2018

The researchers found that the rate of progression-free survival was higher with brigatinib compared with crizotinib (estimated 12-month progression-free survival, 67% vs 43%; hazard ratio for disease progression or death, 0.49).

Vizimpro Approved as First-Line Treatment for EGFR-Mutated Metastatic NSCLC

By September 28, 2018

The approval was based on data from the ARCHER 1050 open-label, active controlled study which randomized patients with unresectable, metastatic NSCLC to treatment with either dacomitinib (N=227) or gefitinib (N=225).

RET Inhibitor Gets Breakthrough Tx Status for NSCLC, Medullary Thyroid Cancer

By September 06, 2018

LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.

Keytruda With Pemetrexed + Platinum Chemotherapy OK'd for Nonsquamous NSCLC

By August 21, 2018

The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm.

Opdivo Approved to Treat Metastatic Small Cell Lung Cancer

By August 20, 2018

Data showed that 12% responded to treatment based on assessment by a Blinded Independent Central Review, regardless of PD-L1 expression; 11% had a partial response, and 1 patient had a complete response (0.9%).

Biomarker Panel May Improve Lung Cancer Risk Assessment

August 06, 2018

The integrated risk prediction model combining smoking exposure with the biomarker score yielded an area under the curve of 0.83 versus 0.73 for a model based on smoking exposure alone.

Skin Appears to Be Key Pathway for Absorption of BBQ Fumes

August 06, 2018

"In the case of BBQ fumes, dermal absorption was a more important pathway for intake of low-molecular-weight PAHs than inhalation," the authors write.

Lurbinectedin Gains Orphan Drug Status for Small Cell Lung Cancer

By August 03, 2018

A Phase 2 multicenter trial examined the safety and efficacy of lurbinectedin in several types of advanced solid tumors, including SCLC.

NIH Releases Large-Scale Dataset of CT Images

August 03, 2018

Unlike most lesion medical image datasets currently available, which can detect only 1 type of lesion, DeepLesion has much diversity and contains critical radiology findings from across the body, including lung nodules, liver tumors, and enlarged lymph nodes.

Link for Asbestos-Free Talcum Powder, Cancer Not Clear

July 19, 2018

Perineal use of talc-based body powder is classified as "possibly carcinogenic to humans."

Ready-to-Administer Gemcitabine Formulation Gets FDA Approval

By July 18, 2018

Infugem utilizes a novel technology that enables cytotoxic oncology products to be premixed in a sterile setting and to be supplied to prescribers in RTA infusion bags.

Physician Sued by Noncompliant Patient After Failing to Follow Up on Test

By July 10, 2018

Timely review and appropriate follow up on all patient reports is essential and must be part of a practice's routine.

Palliative Care Reduces Odds of Suicide in Lung Cancer Patients

June 22, 2018

Only 20% of the patients who died by suicide had a palliative care encounter, compared with 57% among lung cancer patients whose cause of death was not suicide.

ASCO: New Assays May Detect Early Lung Cancer in Blood

June 06, 2018

The researchers found that more than 50% of the 3,055 nonsynonymous mutations detected across 122 evaluable patients with lung cancer were detected in WBC consistent with clonal hematopoiesis.

Alimta Labeling Updated to Include Combo Treatment for NSCLC

By June 05, 2018

Merck initially gained accelerated approval for Keytruda with Alimta and carboplatin in May 2017.

Pembrolizumab Superior for Initial Tx of Advanced NSCLC

June 04, 2018

The researchers found that 13.7 and 4.9% of patients were still on pembrolizumab and were on pemetrexed maintenance, respectively, after a median follow-up of 12.8 months.

Hypofractionated Radiotherapy Best in Anaplastic Thyroid Cancer

May 30, 2018

"Our findings demonstrate the heterogeneity of response to radiation in ATC tumors and superiority of hypofractionated RT in improving local control, metastatic spread, and survival in preclinical models," the authors write.

Prediction Tool Helps Tailor Lung Cancer Screening to Patients

May 30, 2018

"Identifying circumstances in which LDCT screening is more versus less preference-sensitive may help clinicians personalize their screening discussions, tailoring to both preferences and clinical benefit," the authors write.

Risk Models Help Select Ever Smokers for Lung CA Screening

May 15, 2018

The researchers found that the models chose US screening populations ranging from 7.6 to 26 million ever-smokers.

Cancer Incidences and Burden Expected to Shift in HIV-Positive

May 08, 2018

The estimated total cancer burden in PLWH will decrease from 8,150 cases in 2010 to 6,690 cases in 2030, with prostate and lung cancer projected to be the most common cancer types.

Tagrisso Approved as First-Line Treatment for EGFR-Mutated NSCLC

By April 19, 2018

Results showed that progression-free survival (PFS), the primary endpoint, was significantly longer in Tagrisso-treated patients vs EGFR tyrosine kinase inhibitor-treated patients (18.9 months vs 10.2 months; hazard ratio [HR] 0.46, 95% CI: 0.37, 0.57; P <.0001).

Considerable Differences in Burden of Disease at State Level

April 11, 2018

The highest and lowest life expectancies at birth were seen for Hawaii (81.3 years) and Mississippi (74.7 years) in 2016.

Dacomitinib Granted Priority Review for NSCLC With EGFR-Activating Mutations

By April 04, 2018

Dacomitinib is a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

Opioid Rx Patterns Examined for Head and Neck, Lung and Colon Cancer

March 12, 2018

The researchers identified 168 prescriptions associated with HNCA and 571 with LCCA diagnoses. Compared to patients with LCCA, patients with HNCA had significantly increased odds of being prescribed an opioid (odds ratio, 1.68).

FDA Approves New Dosing Option for Opdivo

By March 06, 2018

This approval will provide healthcare professionals the flexibility to customize patient care.

Imfinzi Approved to Treat Stage III Non-Small Cell Lung Cancer

By February 20, 2018

The approval of Imfinzi is based on the positive PFS data from the Phase 3 PACIFIC trial.